SEC Form 4 · accession 0001209191-19-018278
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James A Schoeneck
Director
Period of report
Mar 7, 2019
Accepted (ET)
Mar 8, 2019 · 6:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 7, 2019 | M | 2,000 | $2.90 | A | 29,700 | D | |
| Common StockF1,F2 | Mar 7, 2019 | S | 1,620 | $54.62 | D | 28,080 | D | |
| Common StockF1,F3 | Mar 7, 2019 | S | 380 | $55.23 | D | 27,700 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $2.90 | Mar 7, 2019 | M | 2,000 | D | — | Apr 27, 2020 | Common Stock | 2,000 | 6,000 | D |
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 plan.
- F2The shares were sold at prices ranging from $54.05 to $55.04. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The shares were sold at prices ranging from $55.05 to $55.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4Fully vested.